Brookstone Capital Management Sells 6,299 Shares of AbbVie Inc. $ABBV

Brookstone Capital Management cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 6.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 91,414 shares of the company’s stock after selling 6,299 shares during the quarter. Brookstone Capital Management’s holdings in AbbVie were worth $20,887,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the second quarter valued at approximately $26,000. Chelsea Counsel Co. purchased a new position in shares of AbbVie in the third quarter worth $26,000. Westend Capital Management LLC purchased a new position in shares of AbbVie in the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX bought a new stake in AbbVie during the 3rd quarter valued at $31,000. Finally, Caitlin John LLC bought a new stake in AbbVie during the 3rd quarter valued at $33,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Up 1.8%

Shares of NYSE ABBV opened at $213.12 on Tuesday. The firm has a fifty day simple moving average of $221.93 and a two-hundred day simple moving average of $224.66. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The firm has a market capitalization of $376.83 billion, a PE ratio of 90.30, a price-to-earnings-growth ratio of 0.73 and a beta of 0.34.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the previous year, the firm posted $2.16 EPS. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s dividend payout ratio is 293.22%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ABBV. Barclays assumed coverage on shares of AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Piper Sandler raised their target price on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Morgan Stanley boosted their price target on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Finally, Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $253.15.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.08% of the stock is currently owned by corporate insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.